Florén C H, Chen C H, Franzén J, Albers J J
Department of Medicine, University Hospital, Lund, Sweden.
Scand J Clin Lab Invest. 1987 Oct;47(6):613-7. doi: 10.1080/00365518709168477.
Lecithin: cholesterol acyltransferase (LCAT) activity in patients with liver disease has been found to be either normal or lower than normal, but no information on LCAT mass in these patients is available. In this study, LCAT mass concentration together with LCAT activity and cholesterol esterification rate were measured in the plasma of 19 patients with cholestatic liver disease and 21 patients with non-cholestatic liver disease. The LCAT mass in plasma correlated positively with serum albumin (r = 0.69, p less than 0.001) and pre-albumin (r = 0.77, p less than 0.001) and negatively with serum bilirubin (r = -0.42, p less than 0.01) and bile salts (r = -0.43, p less than 0.01), thus reflecting the severity of liver disease and liver protein synthesizing capacity. In plasma, LCAT mass concentration also correlated well with LCAT activity (r = 0.88, p less than 0.001) and cholesterol esterification rate (r = 0.73, p less than 0.001), thereby indicating that the decrease of LCAT activity and cholesterol esterification rate in liver disease is primarily a function of decreased LCAT mass.
胆固醇酰基转移酶（LCAT）在肝病患者中的活性已被发现要么正常，要么低于正常水平，但关于这些患者LCAT质量的信息尚无可用数据。在本研究中，对19例胆汁淤积性肝病患者和21例非胆汁淤积性肝病患者的血浆进行了LCAT质量浓度、LCAT活性和胆固醇酯化率的测定。血浆中的LCAT质量与血清白蛋白呈正相关（r = 0.69，p小于0.001）和前白蛋白呈正相关（r = 0.77，p小于0.001），与血清胆红素呈负相关（r = -0.42，p小于0.01）和胆汁盐呈负相关（r = -0.43，p小于0.01），从而反映了肝病的严重程度和肝脏蛋白质合成能力。在血浆中，LCAT质量浓度也与LCAT活性（r = 0.88，p小于0.001）和胆固醇酯化率（r = 0.73，p小于0.001）密切相关，由此表明肝病中LCAT活性和胆固醇酯化率的降低主要是LCAT质量降低的作用。
